v3.24.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Net revenue:      
Total net revenue $ 591,643 $ 509,728 $ 484,329
COST OF REVENUE 347,039 321,832 297,269
GROSS PROFIT 244,604 187,896 187,060
Operating expenses:      
General and administrative 243,101 243,356 221,347
Research and development 27,309 30,326 21,873
Sales and marketing 70,842 67,321 62,594
Restructuring charges 11,088 4,516 0
Total operating expenses 352,340 345,519 305,814
LOSS FROM OPERATIONS (107,736) (157,623) (118,754)
Interest income (16,902) (6,075) (3,138)
Interest expense 6,907 7,581 8,220
Other expense (income), net (644) 213 499
Gain on investment in and loan receivable from non-consolidated affiliate, net 0 0 (109,260)
Loss before taxes (97,097) (159,342) (15,075)
Income tax benefit (9,129) (15,092) (6,728)
NET LOSS $ (87,968) $ (144,250) $ (8,347)
NET LOSS PER SHARE      
Basic (in dollars per share) $ (0.70) $ (1.16) $ (0.07)
Diluted (in dollars per share) $ (0.70) $ (1.16) $ (0.07)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING      
Basic (in shares) 125,502 124,217 119,962
Diluted (in shares) 125,502 124,217 119,962
Clinical Services      
Net revenue:      
Total net revenue $ 495,636 $ 418,754 $ 404,172
COST OF REVENUE 287,059 261,742 244,360
GROSS PROFIT 208,577 157,012 159,812
Advanced Diagnostics      
Net revenue:      
Total net revenue 96,007 90,974 80,157
COST OF REVENUE 59,980 60,090 52,909
GROSS PROFIT $ 36,027 $ 30,884 $ 27,248

Source